Pimavanserin
ApprovedWithdrawn 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Insomnia Chronic
Conditions
Insomnia Chronic, Posttraumatic Stress Disorder
Trial Timeline
Dec 15, 2022 → Dec 15, 2023
NCT ID
NCT04809116About Pimavanserin
Pimavanserin is a approved stage product being developed by Acadia Pharmaceuticals for Insomnia Chronic. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04809116. Target conditions include Insomnia Chronic, Posttraumatic Stress Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Insomnia Chronic were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05796167 | Phase 1 | Withdrawn |
| NCT05357612 | Approved | Recruiting |
| NCT04809116 | Approved | Withdrawn |
| NCT05555615 | Phase 2/3 | Terminated |
| NCT04292223 | Approved | Completed |
| NCT04000009 | Phase 3 | Terminated |
| NCT03623321 | Phase 3 | Completed |
| NCT03482882 | Phase 2 | Completed |
| NCT03118947 | Phase 2 | Completed |
| NCT03121586 | Phase 3 | Terminated |
| NCT03018340 | Phase 2 | Completed |
Competing Products
20 competing products in Insomnia Chronic